Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, HC Wainwright Analyst Says

Kura Oncology (NASDAQ:KURA) had its price target raised by research analysts at HC Wainwright from $37.00 to $40.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 341.99% from the company’s previous close.

Several other analysts have also recently weighed in on the stock. Bank of America dropped their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. Scotiabank dropped their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. UBS Group started coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, Jefferies Financial Group reduced their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.75.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $9.05 on Thursday. The business’s 50 day moving average is $8.83 and its 200-day moving average is $15.16. The firm has a market cap of $703.73 million, a P/E ratio of -3.83 and a beta of 0.78. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same period last year, the company posted ($0.50) EPS. Equities research analysts predict that Kura Oncology will post -2.44 earnings per share for the current year.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,255 shares of company stock valued at $100,739. 5.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kura Oncology

Institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC bought a new position in Kura Oncology during the 3rd quarter worth approximately $25,000. Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology during the third quarter worth $146,000. Erste Asset Management GmbH bought a new position in Kura Oncology during the third quarter worth $215,000. Bellevue Group AG lifted its holdings in Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Kura Oncology during the third quarter valued at $268,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.